Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (NCT05003986)
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 1 Year to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (47 Sites)
Showing the first 25 of 47 sites.
- Cedars-Sinai Medical Center — Los Angeles, California
- Nemours Children's Hospital — Wilmington, Delaware
- University of Miami, Leonard M. Miller School of Medicine — Miami, Florida
- Nicklaus Children's Hospital — Miami, Florida
- University of Iowa, Stead Family Children's Hospital — Iowa City, Iowa
- Floating Hospital for Children at Tufts Medical Center — Boston, Massachusetts
- C.S. Mott Children's Hospital — Ann Arbor, Michigan
- University of Minnesota, Masonic Children's Hospital — Minneapolis, Minnesota
- Children's Mercy Hospitals and Clinics — Kansas City, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- Jersey Shore University Medical Center — Neptune City, New Jersey
- Cohen Children's Medical Center — New Hyde Park, New York
- Fink Children's Ambulatory Care Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Atrium Health Levine Children's Hospital — Charlotte, North Carolina
- Duke Molecular Physiology Institute — Durham, North Carolina
- Nationwide Children's Hospital — Columbus, Ohio
- University of Oklahoma Health Sciences Center (OUHSC) — Oklahoma City, Oklahoma
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- St. Christopher's Hospital for Children — Philadelphia, Pennsylvania
- Texas Children's Hospital — Houston, Texas
- UT Health - John P. and Kathrine G. McGovern Medical School — Houston, Texas
- Seattle Children's Hospital — Seattle, Washington
- Uniklinik Köln, Klinik und Poliklinik für Kinder- und Jugendmedizin — Cologne,
- Universitätsklinikum Hamburg-Eppendorf — Hamburg,
📞 Contact the Study Coordinator
Phone: (877) 659-5518
Email: medinfo@travere.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Focal Segmental Glomerulosclerosis
- Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure — Boston, Massachusetts
- An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases — Bethesda, Maryland
- Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children — Loma Linda, California
- Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System — Loma Linda, California
- A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) — Chula Vista, California
Explore by condition: All Focal Segmental Glomerulosclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.